Finally, the ability to produce a stable and intact TC-CD320 complex, along with knowledge of the binding interface at atomic detail, might facilitate the design and manufacture of small molecule as well as immunotherapeutic regulators that could selectively disrupt the interaction in certain tumours overexpressing CD320. Here, CD320 is linked to neoplasm.